Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2) (Active) Protein

Details zu Produkt Nr. ABIN2017902, Anbieter: Anmelden zum Anzeigen
Proteinname
  • CSF2
  • GM-CSF
  • GMCSF
  • CSF
  • Csfgm
  • Gm-CSf
  • MGI-IGM
  • Gm-csf
  • Gmcsf
  • granulocyte-macrophage colony-stimulating-factor
  • colony stimulating factor 2 (granulocyte-macrophage)
  • granulocyte-macrophage colony-stimulating factor
  • granulocyte-macrophage colony stimulating factor
  • GM-CSF
  • CSF2
  • Csf2
Spezies
Human
77
24
14
6
5
4
2
1
1
1
1
1
1
Quelle
Escherichia coli (E. coli)
65
9
8
7
4
3
3
2
2
2
2
1
1
1
1
1
1
Protein-Typ
Recombinant
Biologische Aktivität
Active
Optionen
Hersteller
Anmelden zum Anzeigen
Hersteller Produkt- Nr.
Anmelden zum Anzeigen
Request

Dieses Produkt umsonst

Schicken Sie uns Ihren Validierungsvorschlag. Ich möchte dieses Produkt validieren

Mehr erfahren

Sequenz MAPARSPSPS TQPWEHVNAI QEARRLLNLS RDTAAEMNET VEVISEMFDL QEPTCLQTRL ELYKQGLRGS LTKLKGPLTM MASHYKQHCP PTPETSCATQ IITFESFKEN
Spezifität UV Scan: The maximal absorption wave is 279+/-3 nm.
Produktmerkmale The ED50 as determined by the dose-dependant stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line) is less than 0.1 ng/mL, corresponding to a Specific Activity of 1.0x10^7 IU/mg.
LKDFLLVIPF DCWEPVQETh e sequence of the first fifteen N-terminal amino acids has been found to be (Met)-Ala-Pro-Ala-Arg-Ser-Pro-Ser-Pro-Ser-Thr-Gln-Pro-Trp-Glu-His.
Reinheit Greater than 98 % as determined by(a) Analysis by SEC-HPLC (b) Analysis by reducing and non-reducing SDS-PAGE silver-stained gel
Endotoxin-Niveau < 0.03 ng/μg (0.3 IEU/μg) determined by LAL test
Hintergrund Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is produced by a number of different cell types, including activated T cells, B cells, macrophages, mast cells, endothelial cells, and fibroblasts, in response to cytokine of immune and inflammatory stimuli. Besides granulocyte-macrophage progenitors, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. On mature hematopoietic, monocytes/macrophages and eosinophils.Human Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) can induce human endothelial cells to migrate and proliferate. Additionally, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma, and adenocarcinoma cell lines.
Synonyms: rHuGM-CSF, GM-CSF
Molekulargewicht 14,000 Da
Forschungsgebiet Cytokines
Pathways JAK-STAT Signalweg, Cellular Response to Molecule of Bacterial Origin
Beschränkungen Nur für Forschungszwecke einsetzbar
Format Lyophilized
Rekonstitution It is recommended that the lyophilized Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) be reconstituted in sterile 18 M omega-cm H2O not less than 100 μg/mL, which can then be further diluted to other aqueous solutions.
Buffer The protein was lyophilized after extensive dialysis against 20 mM Phosphate buffer, pH 7.0, 150 mM NaCl, 5 % Mannitol buffer.
Handhabung Avoid repeated freeze-thaw cycles.
Lagerung -20 °C
Informationen zur Lagerung Lyophilized Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), although stable at room temperature for three weeks, should be stored desiccated at -18 °C or below. Upon reconstitution, Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) may be stored at 4 °C for short periods (two to seven days). For long term storage, it is recommended that a carrier protein (0.1% HSA or BSA) be added.
Produkt verwendet in: Mathew, Zaineb, Verma: "GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells." in: Apoptosis : an international journal on programmed cell death, Vol. 18, Issue 7, pp. 882-95, 2013 (PubMed).

Wang, Thomson, Allan, Jackson, Olson, Hercus, Nero, Turner, Parker, Lopez, Waddell, Anderson, Hamilton, Schrader: "Characterization of pathogenic human monoclonal autoantibodies against GM-CSF." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, Issue 19, pp. 7832-7, 2013 (PubMed).

Côté, Plante, Tardif, Tremblay: "Dectin-1/TLR2 and NOD2 agonists render dendritic cells susceptible to infection by X4-using HIV-1 and promote cis-infection of CD4(+) T cells." in: PLoS ONE, Vol. 8, Issue 7, pp. e67735, 2013 (PubMed).

Bouchlaka, Sckisel, Chen, Mirsoian, Zamora, Maverakis, Wilkins, Alderson, Hsiao, Weiss, Monjazeb, Hesdorffer, Ferrucci, Longo, Blazar, Wiltrout, Redelman, Taub, Murphy: "Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy." in: The Journal of experimental medicine, Vol. 210, Issue 11, pp. 2223-37, 2013 (PubMed).

Allan, Stax, Zheng, Chung, Kozak, Tan, van den Elzen: "CD1d and CD1c expression in human B cells is regulated by activation and retinoic acid receptor signaling." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 186, Issue 9, pp. 5261-72, 2011 (PubMed).

Lambert, Barabé, Gilbert, Tremblay: "DCIR-mediated enhancement of HIV-1 infection requires the ITIM-associated signal transduction pathway." in: Blood, Vol. 117, Issue 24, pp. 6589-99, 2011 (PubMed).

Ciesielski, Ahluwalia, Munich, Orton, Barone, Chanan-Khan, Fenstermaker: "Antitumor cytotoxic T-cell response induced by a survivin peptide mimic." in: Cancer immunology, immunotherapy : CII, Vol. 59, Issue 8, pp. 1211-21, 2010 (PubMed).

Allgemeine Veröffentlichungen Djalilian, Caicedo, Lessan, Grami, Le, Spellman, Pambuccian, Hall, Low, Ondrey: "Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats." in: Cancer immunology, immunotherapy : CII, Vol. 56, Issue 8, pp. 1207-14, 2007 (PubMed).